文献速递胸部肿瘤

大细胞肺癌基因表达谱将转录表型与WHO 2015新组织学分类相关联

Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification.
PubMed 文献 · J Thorac Oncol · 2017-05-20

研究对159例涵盖所有组织学亚型的肺癌样本(含10例WHO 2015分类的大细胞肺癌和14例大细胞神经内分泌癌)进行基因表达谱分析,并在199例独立肿瘤中验证。无监督分析发现90%的WHO 2015大细胞肺癌归入一种低分化增殖性癌表型,TP53突变率90%且缺乏常见NSCLC驱动基因改变;大细胞神经内分泌癌呈现两种转录模式,对应基于TP53和RB1改变的SCLC样与NSCLC样划分。结论支持WHO 2015分类。

要点

  • 90%的WHO 2015大细胞肺癌归入低分化增殖性癌转录表型,TP53突变率90%。
  • 该表型缺乏已知NSCLC致癌驱动基因改变。
  • 大细胞神经内分泌癌按TP53和RB1改变模式分为SCLC样与NSCLC样两种转录模式。

核心结论

  • 分子分析支持WHO 2015对大细胞肺癌和大细胞神经内分泌癌的分类,二者遵循不同肿瘤发生路径并可分层为不同转录亚组。
  • 大细胞肺癌的精细分类对诊断、预后和治疗决策有影响。

研究设计与样本

  • 采用Illumina V4 HT12微阵列对159例样本(涵盖所有组织学亚型,含10例WHO 2015大细胞肺癌和14例大细胞神经内分泌癌)进行基因表达谱分析,并辅以突变和免疫组化数据。
  • 在199例独立肿瘤(含6例WHO 2015大细胞肺癌和5例大细胞神经内分泌癌)中验证所得转录表型。

主要发现

  • 无监督基因表达分析识别出一种包含90%的WHO 2015大细胞肺癌肿瘤的表型,具低分化增殖性癌特征,TP53突变率90%,且缺乏已知NSCLC致癌驱动基因改变。
  • 独立数据验证确认WHO 2015大细胞肺癌聚集于该特定表型。
  • 大细胞神经内分泌癌的无监督基因表达分析提示两种不同转录模式,对应基于TP53和RB1改变模式将大细胞神经内分泌癌分为SCLC样和NSCLC样的遗传划分。

关键数值与推荐

  • WHO 2015分类将大细胞肺癌定义改为基于腺癌和鳞癌的免疫标志物。
  • WHO 2015大细胞肺癌中90%归入低分化增殖性癌表型,该表型TP53突变率为90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Large cell lung cancer (LCLC) and large cell neuroendocrine carcinoma (LCNEC) constitute a small proportion of NSCLC. The WHO 2015 classification guidelines changed the definition of the debated histological subtype LCLC to be based on immunomarkers for adenocarcinoma and squamous cancer. We sought to determine whether these new guidelines also translate into the transcriptional landscape of lung cancer, and LCLC specifically. METHODS: Gene expression profiling was performed by using Illumina V4 HT12 microarrays (Illumina, San Diego, CA) on samples from 159 cases (comprising all histological subtypes, including 10 classified as LCLC WHO 2015 and 14 classified as LCNEC according to the WHO 2015 guidelines), with complimentary mutational and immunohistochemical data. Derived transcriptional phenotypes were validated in 199 independent tumors, including six WHO 2015 LCLCs and five LCNECs. RESULTS: Unsupervised analysis of gene expression data identified a phenotype comprising 90% of WHO 2015 LCLC tumors, with characteristics of poorly differentiated proliferative cancer, a 90% tumor protein p53 gene (TP53) mutation rate, and lack of well-known NSCLC oncogene driver alterations. Validation in independent data confirmed aggregation of WHO 2015 LCLCs in the specific phenotype. For LCNEC tumors, the unsupervised gene expression analysis suggested two different transcriptional patterns corresponding to a proposed genetic division of LCNEC tumors into SCLC-like and NSCLC-like cancer on the basis of TP53 and retinoblastoma 1 gene (RB1) alteration patterns. CONCLUSIONS: Refined classification of LCLC has implications for diagnosis, prognostics, and therapy decisions. Our molecular analyses support the WHO 2015 classification of LCLC and LCNEC tumors, which herein follow different tumorigenic paths and can accordingly be stratified into different transcriptional subgroups, thus linking diagnostic immunohistochemical staining-driven classification with the transcriptional landscape of lung cancer.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Karlsson A, Brunnström H, Micke P, et al. Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. J Thorac Oncol. 2017. PMID: 28535939. doi:10.1016/j.jtho.2017.05.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。